How pembrolizumab became oncology’s closest thing to a “silver bullet”
Among the available cancer treatments, pembrolizumab is an industry bellwether: A drug that is as close to a “silver bullet” as the industry has ever had in history.
Advisory
Five Organizing Principles for New Product Planning Success
New product planning fails more often than it succeeds. Prescient’s Global Head of Advisory looks at why this happens and outlines a structured approach to fixing the problem.
Five Elements That Make Your Virtual Workshop Deliver Real Value
Virtual workshops have different planning requirements compared to similar events that might take place face to face. Prescient has produced a white paper that details five essential elements for running effective virtual workshops.
Pharma Companies’ Response to the COVID-19 Pandemic
In our previous blog, COVID’s impact on the Pharma industry, we highlighted the major macroeconomic factors that are shaping a difficult time for all industries and showed how Pharma will not escape the worst of it.
COVID-19’s Impact on the Pharma Industry
The COVID-19 pandemic poses the greatest public health emergency for 100 years, coupling high infectivity with a case mortality rate at least five times that of seasonal influenza. With asymptomatic transmission in the mix, the world is battling a perfect storm of infectivity.
Pharma in the Post-COVID Era
Pharma in the post-COVID era – adapting to the new normal is the latest whitepaper from Prescient, providing a comprehensive view of the state of the industry today, its response to COVID-19 and how the future looks for the industry as a whole.
Winning responses to the impact of COVID-19
Prescient’s thought leaders address major shifts in the landscape and outline near-, medium- and long-term choices facing pharma strategy leaders.
Will Your Brand Maintain Its Value in 2020? Key US Market Trends That Should Be Shaping Your Product and Portfolio Strategy
In this white paper, Prescient has identified three industry trends that are shaping competitive dynamics in the US market and how biopharmaceutical companies can optimize the performance of their brands. We discuss the impact and implications of these industry trends on brand teams and the strategies they can leverage to maximize their products’ potential. The following key trends have emerged:
CAR-T: Advancing the Path for Clinical and Commercial Success
With regulatory approval, CAR-T cell therapy must address significant unmet needs in clinical practice without restrictions in order to be successful.
Redefining Access to Novel Cancer Therapies: Exploring Country-Specific Health Policy Changes
Access to cancer therapies is a part of every country’s health policy agenda; it, however, is not guaranteed to the entire clinically eligible population. In the last five years, the market access landscape for cancer therapies has changed significantly with the addition of more treatment options, mainly immunotherapies. High-priced immune checkpoint inhibitors, a new class of anticancer drugs, have shown remarkable promise in the treatment of different cancer types such as melanoma, liver and lung cancers among others.
LinkedIn
Twitter
Facebook